<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Sci Rep</journal-id><journal-id journal-id-type="iso-abbrev">Sci Rep</journal-id><journal-id journal-id-type="pmc-domain-id">1579</journal-id><journal-id journal-id-type="pmc-domain">scirep</journal-id><journal-title-group><journal-title>Scientific Reports</journal-title></journal-title-group><issn pub-type="epub">2045-2322</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11760945</article-id><article-id pub-id-type="pmcid-ver">PMC11760945.1</article-id><article-id pub-id-type="pmcaid">11760945</article-id><article-id pub-id-type="pmcaiid">11760945</article-id><article-id pub-id-type="pmid">39856344</article-id><article-id pub-id-type="doi">10.1038/s41598-025-87678-1</article-id><article-id pub-id-type="publisher-id">87678</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Pharmacovigilance imbalance analysis of VEGFR-TKI-related taste and smell disorders</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Fu</surname><given-names initials="ZH">Zhong-hua</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhao</surname><given-names initials="C">Chenglong</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wang</surname><given-names initials="Y">Yaqin</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhang</surname><given-names initials="L">Lei</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Wang</surname><given-names initials="L">Lei</given-names></name><address><email>chshzx2018@163.com</email></address><xref ref-type="aff" rid="Aff1"/></contrib><aff id="Aff1"><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03f72zw41</institution-id><institution-id institution-id-type="GRID">grid.414011.1</institution-id><institution-id institution-id-type="ISNI">0000 0004 1808 090X</institution-id><institution>Department of pharmacy, School of Clinical Medicine, </institution><institution>Henan Provincial People&#8217;s Hospital, People&#8217;s Hospital of Zhengzhou University, Henan University, </institution></institution-wrap>No.7 Weiwu Road, Jinshui District, Zhengzhou, 450003 Henan China </aff></contrib-group><pub-date pub-type="epub"><day>24</day><month>1</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>15</volume><issue-id pub-id-type="pmc-issue-id">478255</issue-id><elocation-id>3118</elocation-id><history><date date-type="received"><day>23</day><month>7</month><year>2024</year></date><date date-type="accepted"><day>21</day><month>1</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>24</day><month>01</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>26</day><month>01</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-01-29 07:25:26.607"><day>29</day><month>01</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article&#8217;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#8217;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="41598_2025_Article_87678.pdf"/><abstract id="Abs1"><p id="Par1">Taste and smell disorders (TSDs) can induce diminished interest in food, inadequate nutrient intake, and emotional irregularities, particularly among cancer patients. Previous research found that the main culprits of TSD development in cancer patients are cytotoxic drugs such as taxol, fluorouracil, cyclophosphamide, and anthracycline-based drugs. The advent of targeted drugs such as vascular endothelial growth factor receptor-tyrosine kinase inhibitors (VEGFR-TKIs) has significantly extended the survival time of cancer patients, and thus widely used in clinical practice. However, the association between the use of VEGFR-TKIs and the development of TSDs havs not been studied.The adverse event(AE) reports related to VEGFR-TKIs were downloaded from the FDA Adverse Event Reporting System (FAERS) database. Disproportionality analysis was conducted to assess the correlation between VEGFR-TKIs and TSDs. The Standardized Medical Dictionary for Regulatory Activities (MedDRA) Queries (SMQs) were used to analyze the AEs of TSDs. The study found a statistically significant correlation between the occurrence of TSDs and the use of VEGF-TKIs (cabozantinib, axitinib, pazopanib, sunitinib, nintedanib, and lenvatinib).However, the instructions for Nintedanib, Sorafenib and Lenvatinib were not mentioned. Capbottinib demonstrated the highest number of reports(1790 cases), also with the strongest association (ROR 95%CI-low&#8201;=&#8201;16.51; PRR&#8201;=&#8201;16.18; IC025&#8201;=&#8201;3.96) when analyzing the narrow SMQ of TSDs. Dysgeusia, taste disorder, and ageusia were the most commonly reported preferred terms (PTs) in VEGFR-TKI-related TSDs, accounting for more than 90% of the reported cases. Cabozantinib showed the highest number of reports and strongest correlation with ageusia, taste disorder, parosmia, and anosmia. The study found significant association between the reports of TSDs and the use of VEGFR-TKIs, indicating the monitoring of TSD development and appropriate management in clinical is necessary.</p><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1038/s41598-025-87678-1.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Adverse events</kwd><kwd>Cabozantinib</kwd><kwd>Smell disorders</kwd><kwd>Taste disorders</kwd><kwd>VEGFR-TKI</kwd></kwd-group><kwd-group kwd-group-type="npg-subject"><title>Subject terms</title><kwd>Cancer therapy</kwd><kwd>Tumour angiogenesis</kwd><kwd>Tumour-suppressor proteins</kwd><kwd>Kidney</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; Springer Nature Limited 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par2">Tyrosine kinases represent a class of enzymes that catalyze the phosphorylation of tyrosine residues on various substrate proteins using ATP as a phosphate donor and play pivotal roles in mediating cellular growth, proliferation, and differentiation<sup><xref ref-type="bibr" rid="CR1">1</xref></sup>. In recent years, there has been a steady increase in the development of drugs that serve as inhibitors of tyrosine kinases, which can effectively disrupt tyrosine kinase activity, thus curtailing cell proliferation<sup><xref ref-type="bibr" rid="CR2">2</xref></sup>. In particular, vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKIs) include a class of small-molecule drugs targeting VEGFR, by impeding the VEGF signaling pathway to curb vascular proliferation and angiogenesis. Several VEGFR-TKIs were approved by the United States Food and Drug Administration (FDA) for the favorable clinical efficacy in treating a spectrum of solid tumors, including regorafenib, cabozantinib, lenvatinib, axitinib, sunitinib, sorafenib, nintedanib, and pazopanib<sup><xref ref-type="bibr" rid="CR3">3</xref></sup>. The commonly reported adverse events (AEs) of VEGFR-TKIs include diarrhea, fatigue, hand-foot skin syndrome (PPES), hypertension, hypothyroidism, bleeding, and so on<sup><xref ref-type="bibr" rid="CR4">4</xref>,<xref ref-type="bibr" rid="CR5">5</xref></sup>.</p><p id="Par3">Taste and smell disorders (TSDs) are chemosensory disorders that can significantly affect the quality of life for the handicap of food enjoyment and nutrient intake. TSDs are often caused by some underlying diseases, such as diabetes, obesity, and oral diseases<sup><xref ref-type="bibr" rid="CR6">6</xref></sup>. In cancer patients, TSDs have manifested during treatment with cytotoxic drugs such as paclitaxel, fluorouracil, cyclophosphamide, and anthracycline<sup><xref ref-type="bibr" rid="CR7">7</xref></sup>. The drug labels of some VEGFR-TKIs have mentioned the AEs of taste, including axitinib, cabozantinib, pazopanib, regorafenib and sunitinib. A disproportionality analysis revealed a significant association between regorafenib and taste disorders<sup><xref ref-type="bibr" rid="CR8">8</xref></sup>, another study showd taste disorders were reported in 55% of patients treated with regorafenib<sup><xref ref-type="bibr" rid="CR9">9</xref></sup>. A research reported prevalence of protein kinase inhibitors-induced patient-reported taste alterations. Sunitinib showed a prevalence of patient-reported taste alterations varying from 18 to 63%, while sorafenib varied from 3 to 55%<sup><xref ref-type="bibr" rid="CR10">10</xref></sup>. However, the AEs of smell have not been reported or documented in the label yet. Besides, we need more real-world statistics from large-scale users to thoroughly discuss the characteristics and the association of the drugs-related AEs. Therefore, the pharmacovigilance study aimed to analyze data from the US FDA Adverse Event Reporting System (FAERS) to identify possible association between VEGFR-TKIs use and the development of TSDs and provide a comprehensive overview of the clinical characteristics and prognosis.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Data source</title><p id="Par4">Data were obtained from the US Food and Drug Administration Public Data Open Project (Open FDA), which obtained raw data from the FAERS database. Data were extracted by OpenVigil2.1, an open pharmacovigilance data extraction, mining, and analysis tool specifically designed for the FAERS database. OpenVigil2.1 works only on cleaned FDA data, with most duplicates and reports with incomplete information removed.</p><p id="Par5">In the FAERS database, AEs are classified using preferred terms (PTs) from the Medical Dictionary for Regulatory Activities (MedDRA) (version 25.0). A specific PT may be linked with multiple higher-level terms (HLTs), higher-level group terms (HLGTs), and system organ classes (SOCs). Additionally, PTs that indicate symptoms, signs, investigations, or diagnoses of potential significance are organized into Standardized MedDRA Queries (SMQs) to portray specific medical conditions. The research concentrated on the specific SMQ concerning TSDs, including 15 PTs (Table&#160;<xref rid="Tab1" ref-type="table">1</xref>).</p><p id="Par6">
<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table 1</label><caption><p>The PT term and code included in the narrow SMQ of taste and smell disorders.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Preferred Term</th><th align="left" colspan="1" rowspan="1">Code</th><th align="left" colspan="1" rowspan="1">Preferred Term</th><th align="left" colspan="1" rowspan="1">Code</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Hallucination, gustatory</td><td char="." align="char" colspan="1" rowspan="1">10,019,071</td><td align="left" colspan="1" rowspan="1">Congenital anosmia</td><td char="." align="char" colspan="1" rowspan="1">10,079,876</td></tr><tr><td align="left" colspan="1" rowspan="1">Hallucination, olfactory</td><td char="." align="char" colspan="1" rowspan="1">10,019,072</td><td align="left" colspan="1" rowspan="1">Hyposmia</td><td char="." align="char" colspan="1" rowspan="1">10,050,515</td></tr><tr><td align="left" colspan="1" rowspan="1">Dysgeusia</td><td char="." align="char" colspan="1" rowspan="1">10,013,911</td><td align="left" colspan="1" rowspan="1">Anosmia</td><td char="." align="char" colspan="1" rowspan="1">10,002,653</td></tr><tr><td align="left" colspan="1" rowspan="1">Hypergeusia</td><td char="." align="char" colspan="1" rowspan="1">10,069,147</td><td align="left" colspan="1" rowspan="1">Parosmia</td><td char="." align="char" colspan="1" rowspan="1">10,034,018</td></tr><tr><td align="left" colspan="1" rowspan="1">Gustometry abnormal</td><td char="." align="char" colspan="1" rowspan="1">10,064,480</td><td align="left" colspan="1" rowspan="1">Olfactory dysfunction</td><td char="." align="char" colspan="1" rowspan="1">10,086,567</td></tr><tr><td align="left" colspan="1" rowspan="1">Hypogeusia</td><td char="." align="char" colspan="1" rowspan="1">10,020,989</td><td align="left" colspan="1" rowspan="1">Olfactory nerve disorder</td><td char="." align="char" colspan="1" rowspan="1">10,056,388</td></tr><tr><td align="left" colspan="1" rowspan="1">Ageusia</td><td char="." align="char" colspan="1" rowspan="1">10,001,480</td><td align="left" colspan="1" rowspan="1">Olfactory test abnormal</td><td char="." align="char" colspan="1" rowspan="1">10,062,927</td></tr><tr><td align="left" colspan="1" rowspan="1">Taste disorder</td><td char="." align="char" colspan="1" rowspan="1">10,082,490</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr></tbody></table></table-wrap>
</p></sec><sec id="Sec4"><title>Data extraction</title><p id="Par7">In the study, the data for each drug from the first quarter of 2006 to the third quarter of 2023 were collected for retrospective analysis in the FAERS database. VEGFR-TKI (axitinib, nintedanib, sorafenib, cabozantinib, regorafenib, pazopanib, sunitinib, and lenvatinib) were identified as primary or secondary suspects in the reports. Prior to analysis, duplicate entries with the same number were deleted and the same information, such as patient demographics, drugs, and AE, were merged, see Figure <xref rid="MOESM1" ref-type="media">S1</xref>. The association between the narrow-SMQ and PTs of TSDs with VEGFR-TKIs was analyzed .</p></sec><sec id="Sec5"><title>Data mining</title><p id="Par8">A disproportionality analysis was performed using a case/non-case methodology. The Reporting Odds Ratio (ROR)<sup><xref ref-type="bibr" rid="CR11">11</xref></sup> and proportional reporting ratio (PRR)<sup><xref ref-type="bibr" rid="CR12">12</xref></sup>, were calculated to identify potential reporting disproportionality signals in TSDs related to VEGFR-TKI. An exploratory disproportionality approach comparing ADRs related to VEGFR-TKI versus all other drugs (non-cases) reported in the FAERS database was conducted<sup><xref ref-type="bibr" rid="CR13">13</xref></sup>. All TSDs with a significant ROR (lower limit of the 95% CI&#8201;&gt;&#8201;1 with at least 3 cases) were carefully considered unexpected if they were not reported in the FDA label at the time of the study. The Bayesian Information Component (IC)<sup><xref ref-type="bibr" rid="CR14">14</xref></sup>, estimated as significant by the 95% credibility interval&#8201;&gt;&#8201;0 (IC025&#8201;&gt;&#8201;0), which is more accurate with a low number of reports, was calculated to decrease the risk of detecting false signals<sup><xref ref-type="bibr" rid="CR15">15</xref></sup>. The equations and criteria for the three algorithms are shown in Table&#160;<xref rid="Tab2" ref-type="table">2</xref>.</p><p id="Par9">
<table-wrap id="Tab2" position="float" orientation="portrait"><label>Table 2</label><caption><p>Summary of major algorithms applied for signal detection.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Algorithms</th><th align="left" colspan="1" rowspan="1">Equation<sup>#</sup></th><th align="left" colspan="1" rowspan="1">Criteria</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">ROR</td><td align="left" colspan="1" rowspan="1"><p>ROR=(a/b)/(c/d)</p><p>95%CI&#8201;=&#8201;e<sup>ln(ROR)&#177;1.96(1/a+1/b+1/c+1/d)^0.5</sup></p></td><td align="left" colspan="1" rowspan="1">95%CI-low&#8201;&gt;&#8201;1, <italic toggle="yes">N</italic>&#8201;&#8805;&#8201;3</td></tr><tr><td align="left" colspan="1" rowspan="1">PRR</td><td align="left" colspan="1" rowspan="1"><p>PRR=(a/(a&#8201;+&#8201;c))/(b/(b&#8201;+&#8201;d))</p><p>&#967;2 =&#8721;[(O-E)2/E], [O&#8201;=&#8201;a, E =(a&#8201;+&#8201;b)(a&#8201;+&#8201;c)/(a&#8201;+&#8201;b&#8201;+&#8201;c&#8201;+&#8201;d)]</p></td><td align="left" colspan="1" rowspan="1"><p>PRR&#8201;&#8805;&#8201;2, &#967;2&#8201;&#8805;&#8201;4,</p><p><italic toggle="yes">N</italic>&#8201;&#8805;&#8201;3</p></td></tr><tr><td align="left" colspan="1" rowspan="1">BCPNN</td><td align="left" colspan="1" rowspan="1"><p>IC&#8201;=&#8201;log<sub>2</sub>a(a&#8201;+&#8201;b&#8201;+&#8201;c&#8201;+&#8201;d)/((a&#8201;+&#8201;c)(a&#8201;+&#8201;b))</p><p>IC025&#8201;=&#8201;e<sup>ln(IC)&#8722;1.96(1/a+1/b+1/c+1/d)^0.5</sup></p></td><td align="left" colspan="1" rowspan="1">IC025&#8201;&gt;&#8201;0</td></tr></tbody></table><table-wrap-foot><p><sup>#</sup> a: number of reports containing both the suspect drug and the suspect adverse drug reaction. b: number of reports containing the suspect adverse drug reaction with other medications (except the drug of interest). c: number of reports containing the suspect drug with other adverse drug reactions (except the event of interest). d: number of reports containing other medications and other adverse drug reactions.ROR, reporting odds ratio; CI, confidence interval; N, the number of co-occurrences; PRR, proportional reporting ratio; &#967;2, chi-squared; BCPNN, Bayesian confidence propagation neural network; IC, information component; IC025, the lower limit of the 95% two-sided CI of the IC;</p></table-wrap-foot></table-wrap>
</p></sec><sec id="Sec6"><title>Statistical analysis</title><p id="Par10">Descriptive analysis was performed to summarize the clinical characteristics of TSDs-related individuals associated with VEGFR-TKIs. The continuous variables was presented as mean&#8201;&#177;&#8201;standard deviation (SD) and frequency variables was expressed as percentages. Pearson&#8217;s chi-squared or Fisher&#8217;s exact test was used to compare the intervention and hospitalization rates of different VEGFR-TKIs. All statistical analysis were performed with IBM SPSS Statistics (version 26). Results with a P value less than 0.05 were considered statistically significant.</p></sec></sec><sec id="Sec7"><title>Results</title><sec id="Sec8"><title>Descriptive analysis</title><p id="Par11">The clinical features of individuals with VEGFR-TKI-related TSDs are presented in Table&#160;<xref rid="Tab3" ref-type="table">3</xref>; Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>. The median age was 65.53&#8201;&#177;&#8201;10.68 years, with the exception of nintedanib, which was mostly administered for those in the age range of 70&#8211;79 years. Males were more likely to be affected by TSDs than females, except for Lenvatinib. The TSDs caused by VEGFR-TKIs were primarily observed in North America, accounting for 81.4% of cases. VEGFR-TKIs-related TSDs were first reported with sorafenib and sunitinib in 2006. Since the launch of cabozantinib in 2012, the reported amount of TSD-related cases had shown a consistent increase, with 1790 cases reported by the third quarter of 2023.</p><p id="Par12">
<table-wrap id="Tab3" position="float" orientation="portrait"><label>Table 3</label><caption><p>The clinical characteristics of patients with VEGF-TKI related taste and smell disorders.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="2" rowspan="1">Drug</th><th align="left" colspan="1" rowspan="1">Axitinib</th><th align="left" colspan="1" rowspan="1">Nintedanib</th><th align="left" colspan="1" rowspan="1">Sorafenib</th><th align="left" colspan="1" rowspan="1">Cabozantinib</th><th align="left" colspan="1" rowspan="1">Regorafenib</th><th align="left" colspan="1" rowspan="1">Pazopanib</th><th align="left" colspan="1" rowspan="1">Sunitinib</th><th align="left" colspan="1" rowspan="1">Lenvatinib</th></tr></thead><tbody><tr><td align="left" colspan="2" rowspan="1">Launch Time</td><td align="left" colspan="1" rowspan="1">2012.01</td><td align="left" colspan="1" rowspan="1">2014.10</td><td align="left" colspan="1" rowspan="1">2005.12</td><td align="left" colspan="1" rowspan="1">2012.11</td><td align="left" colspan="1" rowspan="1">2012.08</td><td align="left" colspan="1" rowspan="1">2009.10</td><td align="left" colspan="1" rowspan="1">2006.01</td><td align="left" colspan="1" rowspan="1">2015.02</td></tr><tr><td align="left" colspan="2" rowspan="1">N</td><td align="left" colspan="1" rowspan="1">200</td><td align="left" colspan="1" rowspan="1">323</td><td align="left" colspan="1" rowspan="1">119</td><td align="left" colspan="1" rowspan="1">1790</td><td align="left" colspan="1" rowspan="1">34</td><td align="left" colspan="1" rowspan="1">620</td><td align="left" colspan="1" rowspan="1">894</td><td align="left" colspan="1" rowspan="1">221</td></tr><tr><td align="left" rowspan="3" colspan="1">Gender</td><td align="left" colspan="1" rowspan="1">M</td><td align="left" colspan="1" rowspan="1">153(76.5%)</td><td align="left" colspan="1" rowspan="1">197(61.0%)</td><td align="left" colspan="1" rowspan="1">80(67.2%)</td><td align="left" colspan="1" rowspan="1">1219(68.1%)</td><td align="left" colspan="1" rowspan="1">23(67.6%)</td><td align="left" colspan="1" rowspan="1">347(56.0%)</td><td align="left" colspan="1" rowspan="1">557(62.3%)</td><td align="left" colspan="1" rowspan="1">105(47.5%)</td></tr><tr><td align="left" colspan="1" rowspan="1">F</td><td align="left" colspan="1" rowspan="1">43(21.5%)</td><td align="left" colspan="1" rowspan="1">109(33.7%)</td><td align="left" colspan="1" rowspan="1">35(29.4%)</td><td align="left" colspan="1" rowspan="1">550(30.7%)</td><td align="left" colspan="1" rowspan="1">10(29.4%)</td><td align="left" colspan="1" rowspan="1">215(34.7%)</td><td align="left" colspan="1" rowspan="1">312(34.9%)</td><td align="left" colspan="1" rowspan="1">112(50.7%)</td></tr><tr><td align="left" colspan="1" rowspan="1">null</td><td align="left" colspan="1" rowspan="1">4(2.0%)</td><td align="left" colspan="1" rowspan="1">17(5.3%)</td><td align="left" colspan="1" rowspan="1">4(3.4%)</td><td align="left" colspan="1" rowspan="1">21(1.2%)</td><td align="left" colspan="1" rowspan="1">1(2.9%)</td><td align="left" colspan="1" rowspan="1">58(9.4%)</td><td align="left" colspan="1" rowspan="1">25(2.8%)</td><td align="left" colspan="1" rowspan="1">4(1.8%)</td></tr><tr><td align="left" rowspan="7" colspan="1">Age</td><td align="left" colspan="1" rowspan="1">&lt;40</td><td align="left" colspan="1" rowspan="1">1(0.5%)</td><td align="left" colspan="1" rowspan="1">/</td><td align="left" colspan="1" rowspan="1">/</td><td align="left" colspan="1" rowspan="1">28(1.6%)</td><td align="left" colspan="1" rowspan="1">/</td><td align="left" colspan="1" rowspan="1">6(1.0%)</td><td align="left" colspan="1" rowspan="1">7(0.8%)</td><td align="left" colspan="1" rowspan="1">1(0.5%)</td></tr><tr><td align="left" colspan="1" rowspan="1">40&#8211;59</td><td align="left" colspan="1" rowspan="1">55(27.5%)</td><td align="left" colspan="1" rowspan="1">12(3.7%)</td><td align="left" colspan="1" rowspan="1">14(11.8%)</td><td align="left" colspan="1" rowspan="1">219(12.2%)</td><td align="left" colspan="1" rowspan="1">10(29.4%)</td><td align="left" colspan="1" rowspan="1">66(10.6%)</td><td align="left" colspan="1" rowspan="1">211(23.6%)</td><td align="left" colspan="1" rowspan="1">17(7.7%)</td></tr><tr><td align="left" colspan="1" rowspan="1">60&#8211;69</td><td align="left" colspan="1" rowspan="1">73(36.5%)</td><td align="left" colspan="1" rowspan="1">46(14.2%)</td><td align="left" colspan="1" rowspan="1">45(37.8%)</td><td align="left" colspan="1" rowspan="1">353(19.7%)</td><td align="left" colspan="1" rowspan="1">13(38.2%)</td><td align="left" colspan="1" rowspan="1">85(13.7%)</td><td align="left" colspan="1" rowspan="1">274(30.6%)</td><td align="left" colspan="1" rowspan="1">42(19.0%)</td></tr><tr><td align="left" colspan="1" rowspan="1">70&#8211;79</td><td align="left" colspan="1" rowspan="1">47(23.5%)</td><td align="left" colspan="1" rowspan="1">112(34.7%)</td><td align="left" colspan="1" rowspan="1">35(29.4%)</td><td align="left" colspan="1" rowspan="1">261(14.6%)</td><td align="left" colspan="1" rowspan="1">3(8.8%)</td><td align="left" colspan="1" rowspan="1">60(9.7%)</td><td align="left" colspan="1" rowspan="1">190(21.3%)</td><td align="left" colspan="1" rowspan="1">39(17.6%)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8805;&#8201;80</td><td align="left" colspan="1" rowspan="1">11(5.5%)</td><td align="left" colspan="1" rowspan="1">50(15.5%)</td><td align="left" colspan="1" rowspan="1">7(5.9%)</td><td align="left" colspan="1" rowspan="1">63(3.5%)</td><td align="left" colspan="1" rowspan="1">/</td><td align="left" colspan="1" rowspan="1">9(1.5%)</td><td align="left" colspan="1" rowspan="1">44(4.9%)</td><td align="left" colspan="1" rowspan="1">11(5.0%)</td></tr><tr><td align="left" colspan="1" rowspan="1">null</td><td align="left" colspan="1" rowspan="1">13(6.5%)</td><td align="left" colspan="1" rowspan="1">103(31.9%)</td><td align="left" colspan="1" rowspan="1">18(15.1%)</td><td align="left" colspan="1" rowspan="1">866(48.4%)</td><td align="left" colspan="1" rowspan="1">8(23.5%)</td><td align="left" colspan="1" rowspan="1">394(63.5%)</td><td align="left" colspan="1" rowspan="1">168(18.8%)</td><td align="left" colspan="1" rowspan="1">111(50.2%)</td></tr><tr><td align="left" colspan="1" rowspan="1">M&#8201;&#177;&#8201;SD</td><td align="left" colspan="1" rowspan="1">64.98&#8201;&#177;&#8201;8.91</td><td align="left" colspan="1" rowspan="1">73.68&#8201;&#177;&#8201;7.68</td><td align="left" colspan="1" rowspan="1">67.85&#8201;&#177;&#8201;9.05</td><td align="left" colspan="1" rowspan="1">64.48&#8201;&#177;&#8201;11.09</td><td align="left" colspan="1" rowspan="1">61.58&#8201;&#177;&#8201;6.88</td><td align="left" colspan="1" rowspan="1">63.50&#8201;&#177;&#8201;10.79</td><td align="left" colspan="1" rowspan="1">64.64&#8201;&#177;&#8201;10.46</td><td align="left" colspan="1" rowspan="1">67.95&#8201;&#177;&#8201;10.62</td></tr><tr><td align="left" rowspan="4" colspan="1">Reporter region</td><td align="left" colspan="1" rowspan="1">North america</td><td align="left" colspan="1" rowspan="1">169(84.5%)</td><td align="left" colspan="1" rowspan="1">249(77.1%)</td><td align="left" colspan="1" rowspan="1">71(59.7%)</td><td align="left" colspan="1" rowspan="1">1558(87.0%)</td><td align="left" colspan="1" rowspan="1">25(73.5%)</td><td align="left" colspan="1" rowspan="1">468(75.5%)</td><td align="left" colspan="1" rowspan="1">711(79.5%)</td><td align="left" colspan="1" rowspan="1">169(76.5%)</td></tr><tr><td align="left" colspan="1" rowspan="1">Europe</td><td align="left" colspan="1" rowspan="1">1(0.5%)</td><td align="left" colspan="1" rowspan="1">28(8.7%)</td><td align="left" colspan="1" rowspan="1">10(8.4%)</td><td align="left" colspan="1" rowspan="1">91(5.1%)</td><td align="left" colspan="1" rowspan="1">3(8.8%)</td><td align="left" colspan="1" rowspan="1">69(11.1%)</td><td align="left" colspan="1" rowspan="1">68(7.6%)</td><td align="left" colspan="1" rowspan="1">5(2.3%)</td></tr><tr><td align="left" colspan="1" rowspan="1">Asia</td><td align="left" colspan="1" rowspan="1">24(12.0%)</td><td align="left" colspan="1" rowspan="1">16(5.0%)</td><td align="left" colspan="1" rowspan="1">33(27.7%)</td><td align="left" colspan="1" rowspan="1">128(7.2%)</td><td align="left" colspan="1" rowspan="1">4(11.8%)</td><td align="left" colspan="1" rowspan="1">33(5.3%)</td><td align="left" colspan="1" rowspan="1">38(4.3%)</td><td align="left" colspan="1" rowspan="1">40(18.1%)</td></tr><tr><td align="left" colspan="1" rowspan="1">other</td><td align="left" colspan="1" rowspan="1">6(3.0%)</td><td align="left" colspan="1" rowspan="1">30(9.3%)</td><td align="left" colspan="1" rowspan="1">5(4.2%)</td><td align="left" colspan="1" rowspan="1">13(0.7%)</td><td align="left" colspan="1" rowspan="1">2(5.9%)</td><td align="left" colspan="1" rowspan="1">50(8.1%)</td><td align="left" colspan="1" rowspan="1">77(8.6%)</td><td align="left" colspan="1" rowspan="1">7(3.2%)</td></tr><tr><td align="left" rowspan="5" colspan="1">Indication</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Renal cancer 120(60.0%)</td><td align="left" colspan="1" rowspan="1"><p>Pulmonary fibrosis</p><p>265(82.0%)</p></td><td align="left" colspan="1" rowspan="1"><p>Liver Cancer</p><p>80(67.2%)</p></td><td align="left" colspan="1" rowspan="1"><p>Renal cancer</p><p>1389(77.6%)</p></td><td align="left" colspan="1" rowspan="1"><p>Colorectal cancer</p><p>27(79.4%)</p></td><td align="left" colspan="1" rowspan="1"><p>Renal cancer</p><p>350(56.5%)</p></td><td align="left" colspan="1" rowspan="1"><p>Renal cancer</p><p>651(72.8%)</p></td><td align="left" colspan="1" rowspan="1"><p>Renal cancer</p><p>111(50.2%)</p></td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Tumor metastasis 6(3.0%)</td><td align="left" colspan="1" rowspan="1">Interstitial lung disease 35(10.8%)</td><td align="left" colspan="1" rowspan="1"><p>Renal cancer</p><p>28(23.5%)</p></td><td align="left" colspan="1" rowspan="1"><p>Tumor metastasis</p><p>153(8.5%)</p></td><td align="left" colspan="1" rowspan="1"><p>Liver Cancer</p><p>2(5.9%)</p></td><td align="left" colspan="1" rowspan="1"><p>Sarcoma</p><p>37(6.0%)</p></td><td align="left" colspan="1" rowspan="1"><p>Gastrointestinal stromal tumour</p><p>66(7.4%)</p></td><td align="left" colspan="1" rowspan="1"><p>Uterine cancer</p><p>67(30.3%)</p></td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"><p>Neoplasm malignant</p><p>5(2.5%)</p></td><td align="left" colspan="1" rowspan="1"><p>Ppulmonary hypertension</p><p>24(7.4%)</p></td><td align="left" colspan="1" rowspan="1"><p>Thyroid cancer</p><p>6(5.0%)</p></td><td align="left" colspan="1" rowspan="1"><p>Thyroid cancer</p><p>101(5.6%)</p></td><td align="left" colspan="1" rowspan="1"><p>Appendix cancer</p><p>2(5.9%)</p></td><td align="left" colspan="1" rowspan="1"><p>Neoplasm malignant</p><p>25(4.0%)</p></td><td align="left" colspan="1" rowspan="1"><p>Neuroendocrine tumour</p><p>35(3.9%)</p></td><td align="left" colspan="1" rowspan="1"><p>Thyroid cancer</p><p>20(9.0%)</p></td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"><p>Bone Cancer</p><p>2(1.0%)</p></td><td align="left" colspan="1" rowspan="1"><p>Lung cancer</p><p>8(2.5%)</p></td><td align="left" colspan="1" rowspan="1"><p>Melanoma</p><p>5(4.2%)</p></td><td align="left" colspan="1" rowspan="1"><p>Liver Cancer</p><p>67(3.7%)</p></td><td align="left" colspan="1" rowspan="1"><p>Anal cancer</p><p>2(5.9%)</p></td><td align="left" colspan="1" rowspan="1"><p>Connective tissue neoplasm</p><p>23(3.7%)</p></td><td align="left" colspan="1" rowspan="1"><p>Lung cancer</p><p>18(2.0%)</p></td><td align="left" colspan="1" rowspan="1"><p>Liver Cancer</p><p>16(7.2%)</p></td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"><p>Brain Tumor</p><p>1(0.5%)</p></td><td align="left" colspan="1" rowspan="1"><p>Diarrhoea</p><p>8(2.5%)</p></td><td align="left" colspan="1" rowspan="1"><p>Lung cancer</p><p>5(4.2%)</p></td><td align="left" colspan="1" rowspan="1"><p>Prostate cancer</p><p>25(1.4%)</p></td><td align="left" colspan="1" rowspan="1"><p>Bone Cancer</p><p>2(5.9%)</p></td><td align="left" colspan="1" rowspan="1"><p>Tumor metastasis</p><p>16(2.6%)</p></td><td align="left" colspan="1" rowspan="1"><p>Tumor metastasis</p><p>18(2.0%)</p></td><td align="left" colspan="1" rowspan="1"><p>Tumor metastasis</p><p>5(2.3%)</p></td></tr><tr><td align="left" rowspan="5" colspan="1">prior/simultaneous drugs</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"><p>Pembrolizumab</p><p>35(17.5%)</p></td><td align="left" colspan="1" rowspan="1"><p>Pirfenidone</p><p>20(6.2%)</p></td><td align="left" colspan="1" rowspan="1"><p>Amlodipine</p><p>9(7.6%)</p></td><td align="left" colspan="1" rowspan="1"><p>Nivolumab</p><p>299(16.7%)</p></td><td align="left" colspan="1" rowspan="1"><p>Trifluridine / tipiracil</p><p>8(23.5%)</p></td><td align="left" colspan="1" rowspan="1"><p>Levothyroxine</p><p>39(6.3%)</p></td><td align="left" colspan="1" rowspan="1"><p>Amlodipine</p><p>93(10.4%)</p></td><td align="left" colspan="1" rowspan="1"><p>Everolimus</p><p>93(42.1%)</p></td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"><p>Levothyroxine</p><p>14(7.0%)</p></td><td align="left" colspan="1" rowspan="1"><p>Apixaban</p><p>19(5.9%)</p></td><td align="left" colspan="1" rowspan="1"><p>Omeprazole</p><p>9(7.6%)</p></td><td align="left" colspan="1" rowspan="1"><p>Levothyroxine</p><p>247(13.8%)</p></td><td align="left" colspan="1" rowspan="1"><p>Irinotecan</p><p>4(11.8%)</p></td><td align="left" colspan="1" rowspan="1"><p>Amlodipine</p><p>25(4.0%)</p></td><td align="left" colspan="1" rowspan="1"><p>Omeprazole</p><p>87(9.7%)</p></td><td align="left" colspan="1" rowspan="1"><p>Pembrolizumab</p><p>63(28.5%)</p></td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"><p>Amlodipine</p><p>11(5.5%)</p></td><td align="left" colspan="1" rowspan="1"><p>Aspirin</p><p>17(5.3%)</p></td><td align="left" colspan="1" rowspan="1"><p>Hydrochlorothiazide</p><p>7(5.9%)</p></td><td align="left" colspan="1" rowspan="1"><p>Amlodipine</p><p>193(10.8%)</p></td><td align="left" colspan="1" rowspan="1"><p>Bevacizumab</p><p>3(8.8%)</p></td><td align="left" colspan="1" rowspan="1"><p>Atorvastatin</p><p>25(4.0%)</p></td><td align="left" colspan="1" rowspan="1"><p>Levothyroxine</p><p>80(8.9%)</p></td><td align="left" colspan="1" rowspan="1"><p>Amlodipine</p><p>26(11.8%)</p></td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"><p>Aspirin</p><p>11(5.5%)</p></td><td align="left" colspan="1" rowspan="1"><p>Loperamide</p><p>17(5.3%)</p></td><td align="left" colspan="1" rowspan="1"><p>Lisinopril</p><p>7(5.9%)</p></td><td align="left" colspan="1" rowspan="1"><p>Metoprolol</p><p>110(6.1%)</p></td><td align="left" colspan="1" rowspan="1"><p>Fluorouracil</p><p>3(8.8%)</p></td><td align="left" colspan="1" rowspan="1"><p>Lisinopril</p><p>22(3.5%)</p></td><td align="left" colspan="1" rowspan="1"><p>Lisinopril</p><p>73(8.2%)</p></td><td align="left" colspan="1" rowspan="1"><p>Gabapentin</p><p>17(7.7%)</p></td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"><p>Atorvastatin</p><p>9(4.5%)</p></td><td align="left" colspan="1" rowspan="1"><p>Treprostinil</p><p>16(5.0%)</p></td><td align="left" colspan="1" rowspan="1"><p>Alprazolam</p><p>6(5.0%)</p></td><td align="left" colspan="1" rowspan="1"><p>Aspirin</p><p>105(5.9%)</p></td><td align="left" colspan="1" rowspan="1"><p>Oxaliplatin</p><p>3(8.8%)</p></td><td align="left" colspan="1" rowspan="1"><p>Aspiri</p><p>21(3.4%)</p></td><td align="left" colspan="1" rowspan="1"><p>Metoprolol</p><p>65(7.3%)</p></td><td align="left" colspan="1" rowspan="1"><p>Levothyroxine</p><p>13(5.9%)</p></td></tr><tr><td align="left" rowspan="3" colspan="1"><p>Out-</p><p>come</p></td><td align="left" colspan="1" rowspan="1">Hospitalization</td><td align="left" colspan="1" rowspan="1">38(19.0%)</td><td align="left" colspan="1" rowspan="1">123(38.1%)</td><td align="left" colspan="1" rowspan="1">54(45.4%)</td><td align="left" colspan="1" rowspan="1">228(12.7%)</td><td align="left" colspan="1" rowspan="1">5(14.7%)</td><td align="left" colspan="1" rowspan="1">66(10.6%)</td><td align="left" colspan="1" rowspan="1">205(22.9%)</td><td align="left" colspan="1" rowspan="1">81(36.7%)</td></tr><tr><td align="left" colspan="1" rowspan="1">Disability</td><td align="left" colspan="1" rowspan="1">/</td><td align="left" colspan="1" rowspan="1">5(1.5%)</td><td align="left" colspan="1" rowspan="1">3(2.5%)</td><td align="left" colspan="1" rowspan="1">5(0.3%)</td><td align="left" colspan="1" rowspan="1">2(5.9%)</td><td align="left" colspan="1" rowspan="1">4(0.6%)</td><td align="left" colspan="1" rowspan="1">19(2.1%)</td><td align="left" colspan="1" rowspan="1">1(0.5%)</td></tr><tr><td align="left" colspan="1" rowspan="1">Death</td><td align="left" colspan="1" rowspan="1">11(5.5%)</td><td align="left" colspan="1" rowspan="1">30(9.3%)</td><td align="left" colspan="1" rowspan="1">29(24.4%)</td><td align="left" colspan="1" rowspan="1">43(2.4%)</td><td align="left" colspan="1" rowspan="1">4(11.8%)</td><td align="left" colspan="1" rowspan="1">19(3.1%)</td><td align="left" colspan="1" rowspan="1">54(6.0%)</td><td align="left" colspan="1" rowspan="1">13(5.9%)</td></tr></tbody></table></table-wrap>
</p><p id="Par13">
<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>The reporting time of patients with VEGF-TKI related taste and smell disorders.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e1118" position="float" orientation="portrait" xlink:href="41598_2025_87678_Fig1_HTML.jpg"/></fig>
</p><p id="Par14">The indications of each VEGFR-TKIs vary, showing in Table&#160;<xref rid="Tab3" ref-type="table">3</xref>. All VEGFR-TKIs were administered orally, and the dosage of most cases were in the range of recommended. Compared with other VEGFR-TKIs mentioned above, individuals taking sorafenib often showed a poorer prognosis, with higher hospitalization and mortality rates. Programmed cell death-1, levothyroxine sodium, and antihypertensive drugs, were the most often co-administered drugs.</p></sec><sec id="Sec9"><title>Bayesian and nonproportional analysis</title><p id="Par15">From the initial marketing of VEGFR-TKI (2006) to the third quarter of 2023, a total of 13,105,775 cases were documented, including 63,956 cases of TSDs. The narrow SMQ of TSDs related to the VEGFR-TKIs were analyzed showing in Table&#160;<xref rid="Tab4" ref-type="table">4</xref>. According to the algorithms, axitinib, nintedanib, cabozantinib, sunitinib, pazopanib, lenvatinib exhibited statistically significant in terms of ROR, PRR and information component (IC). Cabozantinib showed the highest number of cases reported (1790), also with the strongest association with TSDs(ROR 95%CI-low&#8201;=&#8201;16.51; PRR&#8201;=&#8201;16.18; IC025&#8201;=&#8201;3.96). Regorafenib was the least reported drugs, and there was no statistically difference comparerd with the reference group of the FAERS database for the development of TSDs.</p><p id="Par16">
<table-wrap id="Tab4" position="float" orientation="portrait"><label>Table 4</label><caption><p>Signal strength of VEGF-TKI related taste and smell disorders.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Drug</th><th align="left" colspan="1" rowspan="1">
<italic toggle="yes">N</italic>
</th><th align="left" colspan="1" rowspan="1">PRR(&#967;<sup>2</sup>)</th><th align="left" colspan="1" rowspan="1">ROR (95% two-sided CI)</th><th align="left" colspan="1" rowspan="1">IC(95% two-sided CI)</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Axitinib</td><td char="." align="char" colspan="1" rowspan="1">200</td><td char="." align="char" colspan="1" rowspan="1">3.23(306.3)*</td><td char="." align="char" colspan="1" rowspan="1">3.27(2.84&#8211;3.76)*</td><td char="." align="char" colspan="1" rowspan="1">1.68(1.45&#8211;1.96)*</td></tr><tr><td align="left" colspan="1" rowspan="1">Nintedanib</td><td char="." align="char" colspan="1" rowspan="1">323</td><td char="." align="char" colspan="1" rowspan="1">4.73(944.79)*</td><td char="." align="char" colspan="1" rowspan="1">4.82(4.31&#8211;5.38)*</td><td char="." align="char" colspan="1" rowspan="1">2.23(2.04&#8211;2.42)*</td></tr><tr><td align="left" colspan="1" rowspan="1">Sorafenib</td><td char="." align="char" colspan="1" rowspan="1">119</td><td char="." align="char" colspan="1" rowspan="1">1.40(13.18)</td><td char="." align="char" colspan="1" rowspan="1">1.4(1.17&#8211;1.68)</td><td char="." align="char" colspan="1" rowspan="1">0.48(0.18&#8211;0.78)*</td></tr><tr><td align="left" colspan="1" rowspan="1">Cabozantinib</td><td char="." align="char" colspan="1" rowspan="1">1790</td><td char="." align="char" colspan="1" rowspan="1">16.18(24612.29)*</td><td char="." align="char" colspan="1" rowspan="1">17.34(16.51&#8211;18.21)*</td><td char="." align="char" colspan="1" rowspan="1">3.96(3.88&#8211;4.04)*</td></tr><tr><td align="left" colspan="1" rowspan="1">Regorafenib</td><td char="." align="char" colspan="1" rowspan="1">34</td><td char="." align="char" colspan="1" rowspan="1">1.13(0.4)</td><td char="." align="char" colspan="1" rowspan="1">1.13(0.81&#8211;1.59)</td><td char="." align="char" colspan="1" rowspan="1">0.17(-0.4-0.74)</td></tr><tr><td align="left" colspan="1" rowspan="1">Pazopanib</td><td char="." align="char" colspan="1" rowspan="1">620</td><td char="." align="char" colspan="1" rowspan="1">6.54(2886.03)*</td><td char="." align="char" colspan="1" rowspan="1">6.71(6.2&#8211;7.28)*</td><td char="." align="char" colspan="1" rowspan="1">2.69(2.56&#8211;2.82)*</td></tr><tr><td align="left" colspan="1" rowspan="1">Sunitinib</td><td char="." align="char" colspan="1" rowspan="1">894</td><td char="." align="char" colspan="1" rowspan="1">8.51(5866.84)*</td><td char="." align="char" colspan="1" rowspan="1">8.84(8.26&#8211;9.45)*</td><td char="." align="char" colspan="1" rowspan="1">3.07(2.96&#8211;3.18)*</td></tr><tr><td align="left" colspan="1" rowspan="1">Lenvatinib</td><td char="." align="char" colspan="1" rowspan="1">221</td><td char="." align="char" colspan="1" rowspan="1">2.53(202.95)*</td><td char="." align="char" colspan="1" rowspan="1">2.55(2.23&#8211;2.91)*</td><td char="." align="char" colspan="1" rowspan="1">1.33(1.11&#8211;1.55)*</td></tr></tbody></table><table-wrap-foot><p>*: Statistically significant.</p></table-wrap-foot></table-wrap>
</p></sec><sec id="Sec10"><title>Correlation between VEGF-TKIs and PTs included in the narrow SMQ of TSDs</title><p id="Par17">We also conducted a analysis focused on VEGFR-TKIs with PTs including in the narrow SMQ of TSDs in Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>. Dysgeusia, taste disorder, and ageusia were the most commonly reported preferred terms (PTs) in VEGFR-TKI-related TSDs, accounting for more than 90% of the reported cases. Cabozantinib showed the highest number of reports and strongest correlation with ageusia, taste disorder, parosmia, and anosmia. There was a strong correlation between axitinib, cabozantinib, nintedanib, pazopanib, sorafenib, sunitinib use and the reporting of dysgeusia, sunitinib showed the strongest correlation (ROR<sub>95% CI&#8722;low</sub> = 8.71, PRR&#8201;=&#8201;9.22, IC<sub>025</sub>&#8201;=&#8201;3.04). Except for regorafenib, all other VEGFR-TKIs demonstrated statistically significant with ageusia,. Cabozantinib and sunitinib accounted for the largest proportion of cases (62.44%), also showed the highest correlation, with ROR values of 17.89 and 15.05, respectively. For taste disorders, axitinib, cabozantinib, nintedanib, pazopanib, sunitinib, and lenvatinib exhibited statistically correlation. Hypogeusia was significantly correlated with axitinib, cabozantinib, pazopanib, and sunitinib use, among which the correlation between hypogeusia and pazopanib, sunitinib use was higher, with ROR values of 11.10 and 12.41, respectively. .In addition, there were 63 parosmia-related cases, among which axitinib and cabozantinib was strongly correlated with the PT, with ROR values of 2.71 and 3.74, respectively. For anosmia, only cabozantinib showed statistically difference (ROR 95% CI-low&#8201;=&#8201;1.30, PRR&#8201;=&#8201;2.04, IC025&#8201;=&#8201;0.21).</p><p id="Par18">
<fig id="Fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><p>The Correlation between VEGF-TKI and PTs included in the narrow SMQ of taste and smell disorders.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e1275" position="float" orientation="portrait" xlink:href="41598_2025_87678_Fig2_HTML.jpg"/></fig>
</p></sec></sec><sec id="Sec11"><title>Discussion</title><p id="Par19">The purpose of the study was to analyze the association between VEGFR-TKIs and the devolopment of TSDs and meanwhile provided a comprehensive overview of the clinical characteristics and prognosis of various drug interventions.To the best of our knowledge, it is first time to conduct such comprehensive analysis base on real-world clinical data to explore the association between TSDs and different VEGFR-TKIs. The study showed that there was statistically significant association between VEGFR-TKIs and the development of TSDs.</p><p id="Par20">In the present study, we observed a gender-based predisposition towards the development of TSDs subsequent to VEGFR-TKIs administration, with males exhibiting a higher likelihood of TSD onset compared to females. This disparity may be correlated with detrimental lifestyle factors, as evidenced by research indicating that smoking and alcohol consumption can lead to the overstimulation of taste buds, a reduction in their sensory acuity, and the impairment of taste nerve conduction, ultimately resulting in gustatory dysfunction<sup><xref ref-type="bibr" rid="CR16">16</xref>&#8211;<xref ref-type="bibr" rid="CR18">18</xref></sup>. The age of the cases was mainly in the range of 60&#8211;69 years except for nintedanib, which was in 70&#8211;79 years. The reason may be explained by the indication of nintedanib<sup><xref ref-type="bibr" rid="CR19">19</xref></sup>. Previous literature has indicated the onset age of idiopathic pulmonary fibrosis is often higher than that for renal cancer<sup><xref ref-type="bibr" rid="CR20">20</xref>,<xref ref-type="bibr" rid="CR21">21</xref></sup>. Furthermore, our analysis revealed that sorafenib was significantly associated with a poorer prognosis within the cohort of cases treated with VEGFR-TKIs. The association may be attributed to the population receiving sorafenib, as it is predominantly prescribed for hepatocellular carcinoma rather than renal carcinoma. Past studies have shown that liver cancer five year survival rate was significantly higher than that of kidney cancer<sup><xref ref-type="bibr" rid="CR22">22</xref>,<xref ref-type="bibr" rid="CR23">23</xref></sup>, which may account for the observed prognostic differences among individuals treated with sorafenib. These findings highlight the importance of considering gender, age and lifestyle factors in the context of VEGFR-TKI-related TSDs, as well as the prognostic implications in specific oncological populations.</p><p id="Par21">Accoding to the latest FDA label, there was no records of the AEs of taste for nintedanib, sorafenib and lenvatinib, while the AEs of smell for all VEGFR-TKIs have not been documented. The study found potential safety signals between the SMQ of TSDs and nintedanib, sorafenib and lenvatinib. Among them, nintedanib demonstrated the highest association (PRR&#8201;=&#8201;4.73, ROR&#8201;=&#8201;4.82, IC&#8201;=&#8201;2.23), and then lenvatinib (PRR&#8201;=&#8201;2.53, ROR&#8201;=&#8201;2.23, IC&#8201;=&#8201;1.11), sorafenib followed (PRR&#8201;=&#8201;1.40,ROR&#8201;=&#8201;1.40,IC&#8201;=&#8201;0.48). For the AEs of smell, cabozantinib showed strong correlation with hyposmia, anosmia and parosmia, axitinib was associated with hyposmia and parosmia, while pazopanib exhibited association with hyposmia.</p><p id="Par22">The mechanism of VEGFR-TKI-related TSDs remain unclear. Oral toxicity, such as oral mucositis and xerostomia is likely to play an important role in taste alterations<sup><xref ref-type="bibr" rid="CR24">24</xref></sup>. Oral mucositis will damage the epithelial cell membranes and leading to the formation of compounds causing off-flavour taste perceptions<sup><xref ref-type="bibr" rid="CR10">10</xref></sup>. Xerostomia may hampers the solubilising of food particles and thus decreases the presentation of tastants to the taste receptors<sup><xref ref-type="bibr" rid="CR25">25</xref></sup>. Taste receptor cells are epithelial cells located on the tongue and epiglottis. Renewal and reconstruction of taste receptor cells are essential to maintaining their functions and ensuring the long-term stability of the taste system<sup><xref ref-type="bibr" rid="CR26">26</xref></sup>. VEGFR-TKIs may affect the differentiation and proliferation of epithelial cells by inhibiting angiogenesis, and can also affect the migration and proliferation of endothelial cells induced by oral mucosal epithelial cells<sup><xref ref-type="bibr" rid="CR27">27</xref></sup>. VEGFR-TKIs may influence the reconstruction of taste bud cells by inhibiting the Wnt/&#946;-catenin signaling pathway, of which VEGFR1 is a positive regulator<sup><xref ref-type="bibr" rid="CR28">28</xref>,<xref ref-type="bibr" rid="CR29">29</xref></sup>. Apart from angiogenic function, VEGF also acts as a neuronal survival factor, regulating the survival, migration, and proliferation of neurons and glial cells<sup><xref ref-type="bibr" rid="CR30">30</xref></sup>. VEGF binds to neuropilin-1 (NRP1) in the facial branchiomotor (FBM) cell body and controls FBM migration. Smell epithelial cells play a central role in our olfactory system and are responsible for capturing and transmitting odor information<sup><xref ref-type="bibr" rid="CR31">31</xref></sup>. Normally, these cells can repair themselves after injury, however, the repair capacity may be weakened as a result of disease or the use of drugs, leading to olfactory dysfunction<sup><xref ref-type="bibr" rid="CR32">32</xref>,<xref ref-type="bibr" rid="CR33">33</xref></sup>. The binding of VEGFR1 regulates olfactory bulb neurogenesis<sup><xref ref-type="bibr" rid="CR34">34</xref>,<xref ref-type="bibr" rid="CR35">35</xref></sup>. VEGFR-TKIs may inhibit the repair of olfactory epithelial cells after damage by interfering with angiogenesis<sup><xref ref-type="bibr" rid="CR36">36</xref>,<xref ref-type="bibr" rid="CR37">37</xref></sup>. And VEGFR-TKIs have multi-target properties, intervening in nerve repair and neuronal regeneration through multiple pathways, thereby affecting self-repair after weakened or damaged olfactory function<sup><xref ref-type="bibr" rid="CR38">38</xref></sup>.</p><p id="Par23">The study benefits from the analysis of real-world clinical data and data mining techniques, We identified a significant association between reports of TSDs and the use of VEGFR-TKIs, especially we firstly reported the AEs of smell disorders related with a few VEGFR-TKIs, such as cabozantinib, axitinib, nintedanib. However, we also realized there are several limitations. Firstly, our methods were unable to distinguish accurate data from false or inaccurately reported data. Secondly, while we were able to extract statistics from the basic case information, the accuracy of concomitant diseases and medication history was unclear, introducing potential confounding factors and uncertainties into the analysis. Thirdly, data mining using Bayesian and nonproportional analysis can only establish statistical association but not causal relationship between AEs and drugs. The lack of research on VEGFR-TKI-related TSDs makes it challenging to establish a definitive link between the drugs and AEs. Further clinical, anatomical, or imaging studies involving large-scale human populations are necessary to provide more comprehensive explanations.</p></sec><sec id="Sec12" sec-type="supplementary-material"><title>Electronic supplementary material</title><p>Below is the link to the electronic supplementary material.</p><p>
<supplementary-material content-type="local-data" id="MOESM1" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41598_2025_87678_MOESM1_ESM.docx" position="float" orientation="portrait"><caption><p>Supplementary Material 1</p></caption></media></supplementary-material>
</p></sec></body><back><fn-group><fn><p><bold>Publisher&#8217;s note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><notes notes-type="author-contribution"><title>Author contributions</title><p>Zhonghua Fu: Conceptualization, Methodology, Software, Writing-Original draft preparation. Chonglong Zhao, Yaqin Wang, and Lei Zhang Visualization, Investigation, Software. Lei Wang: Data curation, Writing-Reviewing and Editing.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>The data supporting the findings of this study were obtained from the following public database OpenVigil 2.1(https://openvigil.sourceforge.net/),[lUser: welcome; Password: world].</p></notes><notes><title>Declarations</title><notes id="FPar1" notes-type="COI-statement"><title>Competing interests</title><p id="Par26">The authors declare no competing interests.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mustonen</surname><given-names>T</given-names></name><name name-style="western"><surname>Alitalo</surname><given-names>K</given-names></name></person-group><article-title>Endothelial receptor tyrosine kinases involved in angiogenesis</article-title><source>J. cell. Biology May</source><year>1995</year><volume>129</volume><issue>4</issue><fpage>895</fpage><lpage>898</lpage><pub-id pub-id-type="doi">10.1083/jcb.129.4.895</pub-id><pub-id pub-id-type="pmcid">PMC2120485</pub-id><pub-id pub-id-type="pmid">7538139</pub-id></element-citation><mixed-citation id="mc-CR1" publication-type="journal">Mustonen, T. &amp; Alitalo, K. Endothelial receptor tyrosine kinases involved in angiogenesis. <italic toggle="yes">J. Cell. Biol</italic>. <bold>129</bold> (4), 895&#8211;898 (1995).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1083/jcb.129.4.895</pub-id><pub-id pub-id-type="pmcid">PMC2120485</pub-id><pub-id pub-id-type="pmid">7538139</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goel</surname><given-names>S</given-names></name><name name-style="western"><surname>Mani</surname><given-names>S</given-names></name><name name-style="western"><surname>Perez-Soler</surname><given-names>R</given-names></name></person-group><article-title>Tyrosine kinase inhibitors: a clinical perspective</article-title><source>Curr. Oncol. Rep. Jan</source><year>2002</year><volume>4</volume><issue>1</issue><fpage>9</fpage><lpage>19</lpage><pub-id pub-id-type="doi">10.1007/s11912-002-0043-x</pub-id><pub-id pub-id-type="pmid">11734109</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Goel, S., Mani, S. &amp; Perez-Soler, R. Tyrosine kinase inhibitors: A clinical perspective. <italic toggle="yes">Curr. Oncol. Rep. Jan</italic>. <bold>4</bold> (1), 9&#8211;19 (2002).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11912-002-0043-x</pub-id><pub-id pub-id-type="pmid">11734109</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hou</surname><given-names>W</given-names></name><etal/></person-group><article-title>Comparative evaluation of cardiovascular risks among nine FDA-approved VEGFR-TKIs in patients with solid tumors: a bayesian network analysis of randomized controlled trials</article-title><source>J. cancer Res. Clin. Oncol. Aug</source><year>2021</year><volume>147</volume><issue>8</issue><fpage>2407</fpage><lpage>2420</lpage><pub-id pub-id-type="doi">10.1007/s00432-021-03521-w</pub-id><pub-id pub-id-type="pmcid">PMC8236482</pub-id><pub-id pub-id-type="pmid">33725154</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Hou, W. et al. Comparative evaluation of cardiovascular risks among nine FDA-approved VEGFR-TKIs in patients with solid tumors: A bayesian network analysis of randomized controlled trials. <italic toggle="yes">J. Cancer Res. Clin. Oncol</italic>. <bold>147</bold> (8), 2407&#8211;2420 (2021).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00432-021-03521-w</pub-id><pub-id pub-id-type="pmcid">PMC8236482</pub-id><pub-id pub-id-type="pmid">33725154</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>B</given-names></name><etal/></person-group><article-title>Incidence and risk of hypertension associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a comprehensive network meta-analysis of 72 randomized controlled trials involving 30013 patients</article-title><source>Oncotarget Oct.</source><year>2016</year><volume>11</volume><issue>41</issue><fpage>67661</fpage><lpage>67673</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.11813</pub-id><pub-id pub-id-type="pmcid">PMC5341903</pub-id><pub-id pub-id-type="pmid">27602778</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">Liu, B. et al. Incidence and risk of hypertension associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: A comprehensive network meta-analysis of 72 randomized controlled trials involving 30013 patients. <italic toggle="yes">Oncotarget.</italic><bold>11</bold> (41), 67661&#8211;67673 (2016).<pub-id pub-id-type="doi" assigning-authority="pmc">10.18632/oncotarget.11813</pub-id><pub-id pub-id-type="pmcid">PMC5341903</pub-id><pub-id pub-id-type="pmid">27602778</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Funakoshi</surname><given-names>T</given-names></name><name name-style="western"><surname>Latif</surname><given-names>A</given-names></name><name name-style="western"><surname>Galsky</surname><given-names>MD</given-names></name></person-group><article-title>Safety and efficacy of addition of VEGFR and EGFR-family oral small-molecule tyrosine kinase inhibitors to cytotoxic chemotherapy in solid cancers: a systematic review and meta-analysis of randomized controlled trials</article-title><source>Cancer Treat. Reviews Jun</source><year>2014</year><volume>40</volume><issue>5</issue><fpage>636</fpage><lpage>647</lpage><pub-id pub-id-type="doi">10.1016/j.ctrv.2014.02.004</pub-id><pub-id pub-id-type="pmid">24629273</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Funakoshi, T., Latif, A. &amp; Galsky, M. D. Safety and efficacy of addition of VEGFR and EGFR-family oral small-molecule tyrosine kinase inhibitors to cytotoxic chemotherapy in solid cancers: A systematic review and meta-analysis of randomized controlled trials. <italic toggle="yes">Cancer Treat. Rev.</italic><bold>40</bold> (5), 636&#8211;647 (2014).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ctrv.2014.02.004</pub-id><pub-id pub-id-type="pmid">24629273</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Amezaga</surname><given-names>J</given-names></name><etal/></person-group><article-title>Assessing taste and smell alterations in cancer patients undergoing chemotherapy according to treatment</article-title><source>Supportive care cancer: Official J. Multinational Association Supportive Care Cancer Dec.</source><year>2018</year><volume>26</volume><issue>12</issue><fpage>4077</fpage><lpage>4086</lpage><pub-id pub-id-type="doi">10.1007/s00520-018-4277-z</pub-id><pub-id pub-id-type="pmid">29855774</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Amezaga, J. et al. Assessing taste and smell alterations in cancer patients undergoing chemotherapy according to treatment. <italic toggle="yes">Support. Care Cancer Off. J. Multinational Assoc. Support. Care Cancer</italic><bold>26</bold> (12), 4077&#8211;4086 (2018).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00520-018-4277-z</pub-id><pub-id pub-id-type="pmid">29855774</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><mixed-citation publication-type="other">Buttiron Webber, T., Briata, I. M., DeCensi, A., Cevasco, I. &amp; Paleari, L. Taste and smell disorders in cancer treatment: Results from an integrative rapid systematic review. <italic toggle="yes">Int. J. Mol. Sci.</italic><bold>28</bold> ;24(3). (2023).<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms24032538</pub-id><pub-id pub-id-type="pmcid">PMC9916934</pub-id><pub-id pub-id-type="pmid">36768861</pub-id></mixed-citation></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barbieri</surname><given-names>MA</given-names></name><etal/></person-group><article-title>Neuropsychiatric adverse drug reactions with oral tyrosine kinase inhibitors in metastatic colorectal cancer: an analysis from the FDA adverse event reporting system</article-title><source>Front. Oncol.</source><year>2023</year><volume>13</volume><fpage>1268672</fpage><pub-id pub-id-type="doi">10.3389/fonc.2023.1268672</pub-id><pub-id pub-id-type="pmid">38023143</pub-id><pub-id pub-id-type="pmcid">PMC10646181</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Barbieri, M. A. et al. Neuropsychiatric adverse drug reactions with oral tyrosine kinase inhibitors in metastatic colorectal cancer: An analysis from the FDA adverse event reporting system. <italic toggle="yes">Front. Oncol.</italic><bold>13</bold>, 1268672 (2023). Published 2023 Oct 31.<pub-id pub-id-type="pmid">38023143</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fonc.2023.1268672</pub-id><pub-id pub-id-type="pmcid">PMC10646181</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Elst</surname><given-names>JM</given-names></name><etal/></person-group><article-title>Taste, smell and mouthfeel disturbances in patients with gastrointestinal stromal tumors treated with tyrosine-kinase inhibitors</article-title><source>Support Care Cancer</source><year>2022</year><volume>30</volume><issue>3</issue><fpage>2307</fpage><lpage>2315</lpage><pub-id pub-id-type="doi">10.1007/s00520-021-06658-z</pub-id><pub-id pub-id-type="pmid">34727226</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">van Elst, J. M. et al. Taste, smell and mouthfeel disturbances in patients with gastrointestinal stromal tumors treated with tyrosine-kinase inhibitors. <italic toggle="yes">Support. Care Cancer</italic>. <bold>30</bold> (3), 2307&#8211;2315 (2022).<pub-id pub-id-type="pmid">34727226</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00520-021-06658-z</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van der Werf</surname><given-names>A</given-names></name><name name-style="western"><surname>Rovithi</surname><given-names>M</given-names></name><name name-style="western"><surname>Langius</surname><given-names>JAE</given-names></name><name name-style="western"><surname>de van der Schueren</surname><given-names>MAE</given-names></name><name name-style="western"><surname>Verheul</surname><given-names>HMW</given-names></name></person-group><article-title>Insight in taste alterations during treatment with protein kinase inhibitors</article-title><source>Eur. J. Cancer</source><year>2017</year><volume>86</volume><fpage>125</fpage><lpage>134</lpage><pub-id pub-id-type="doi">10.1016/j.ejca.2017.09.006</pub-id><pub-id pub-id-type="pmid">28987769</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">van der Werf, A., Rovithi, M., Langius, J. A. E., de van der Schueren, M. A. E. &amp; Verheul, H. M. W. Insight in taste alterations during treatment with protein kinase inhibitors. <italic toggle="yes">Eur. J. Cancer</italic>. <bold>86</bold>, 125&#8211;134 (2017).<pub-id pub-id-type="pmid">28987769</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejca.2017.09.006</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sakaeda</surname><given-names>T</given-names></name><name name-style="western"><surname>Tamon</surname><given-names>A</given-names></name><name name-style="western"><surname>Kadoyama</surname><given-names>K</given-names></name><name name-style="western"><surname>Okuno</surname><given-names>Y</given-names></name></person-group><article-title>Data mining of the public version of the FDA adverse event reporting system</article-title><source>Int. J. Med. Sci.</source><year>2013</year><volume>10</volume><issue>7</issue><fpage>796</fpage><lpage>803</lpage><pub-id pub-id-type="doi">10.7150/ijms.6048</pub-id><pub-id pub-id-type="pmid">23794943</pub-id><pub-id pub-id-type="pmcid">PMC3689877</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Sakaeda, T., Tamon, A., Kadoyama, K. &amp; Okuno, Y. Data mining of the public version of the FDA adverse event reporting system. <italic toggle="yes">Int. J. Med. Sci.</italic><bold>10</bold> (7), 796&#8211;803 (2013).<pub-id pub-id-type="pmid">23794943</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7150/ijms.6048</pub-id><pub-id pub-id-type="pmcid">PMC3689877</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Slattery</surname><given-names>J</given-names></name><name name-style="western"><surname>Alvarez</surname><given-names>Y</given-names></name><name name-style="western"><surname>Hidalgo</surname><given-names>A</given-names></name></person-group><article-title>Choosing thresholds for statistical signal detection with the proportional reporting ratio</article-title><source>Drug Saf. Aug</source><year>2013</year><volume>36</volume><issue>8</issue><fpage>687</fpage><lpage>692</lpage><pub-id pub-id-type="doi">10.1007/s40264-013-0075-1</pub-id><pub-id pub-id-type="pmid">23754759</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Slattery, J., Alvarez, Y. &amp; Hidalgo, A. Choosing thresholds for statistical signal detection with the proportional reporting ratio. <italic toggle="yes">Drug Saf</italic>. <bold>36</bold> (8), 687&#8211;692 (2013).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40264-013-0075-1</pub-id><pub-id pub-id-type="pmid">23754759</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ji</surname><given-names>LH</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>CL</given-names></name><name name-style="western"><surname>Wang</surname><given-names>YQ</given-names></name><name name-style="western"><surname>Fu</surname><given-names>ZH</given-names></name></person-group><article-title>Bisphosphonates-related tendinopathies and ligament disorders: cases analysis from the U.S. Food and Drug Administration adverse event reporting system</article-title><source>Bone</source><year>2023</year><volume>177</volume><fpage>116919</fpage><pub-id pub-id-type="doi">10.1016/j.bone.2023.116919</pub-id><pub-id pub-id-type="pmid">37739298</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Ji, L. H., Zhao, C. L., Wang, Y. Q. &amp; Fu, Z. H. Bisphosphonates-related tendinopathies and ligament disorders: Cases analysis from the U.S. Food and Drug Administration adverse event reporting system. <italic toggle="yes">Bone</italic><bold>177</bold>, 116919 (2023).<pub-id pub-id-type="pmid">37739298</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bone.2023.116919</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hauben</surname><given-names>M</given-names></name><name name-style="western"><surname>Bate</surname><given-names>A</given-names></name></person-group><article-title>Decision support methods for the detection of adverse events in post-marketing data</article-title><source>Drug Discovery Today Apr</source><year>2009</year><volume>14</volume><issue>7&#8211;8</issue><fpage>343</fpage><lpage>357</lpage><pub-id pub-id-type="doi">10.1016/j.drudis.2008.12.012</pub-id><pub-id pub-id-type="pmid">19187799</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="journal">Hauben, M. &amp; Bate, A. Decision support methods for the detection of adverse events in post-marketing data. <italic toggle="yes">Drug Discov. Today</italic>. <bold>14</bold> (7&#8211;8), 343&#8211;357 (2009).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.drudis.2008.12.012</pub-id><pub-id pub-id-type="pmid">19187799</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Harpaz</surname><given-names>R</given-names></name><etal/></person-group><article-title>Performance of pharmacovigilance signal-detection algorithms for the FDA adverse event reporting system</article-title><source>Clin. Pharmacol. Ther.</source><year>2013</year><volume>93</volume><issue>6</issue><fpage>539</fpage><lpage>546</lpage><pub-id pub-id-type="doi">10.1038/clpt.2013.24</pub-id><pub-id pub-id-type="pmid">23571771</pub-id><pub-id pub-id-type="pmcid">PMC3857139</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Harpaz, R. et al. Performance of pharmacovigilance signal-detection algorithms for the FDA adverse event reporting system. <italic toggle="yes">Clin. Pharmacol. Ther.</italic><bold>93</bold> (6), 539&#8211;546 (2013).<pub-id pub-id-type="pmid">23571771</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/clpt.2013.24</pub-id><pub-id pub-id-type="pmcid">PMC3857139</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><mixed-citation publication-type="other">Naimi, B. R. et al. Patient insights into the diagnosis of smell and taste disorders in the United States. <italic toggle="yes">Preprint medRxiv</italic> (2023). 2023.09.20.23295861.</mixed-citation></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ajmani</surname><given-names>GS</given-names></name><name name-style="western"><surname>Suh</surname><given-names>HH</given-names></name><name name-style="western"><surname>Wroblewski</surname><given-names>KE</given-names></name><name name-style="western"><surname>Pinto</surname><given-names>JM</given-names></name></person-group><article-title>Smoking and olfactory dysfunction: a systematic literature review and meta-analysis</article-title><source>Laryngoscope</source><year>2017</year><volume>127</volume><issue>8</issue><fpage>1753</fpage><lpage>1761</lpage><pub-id pub-id-type="doi">10.1002/lary.26558</pub-id><pub-id pub-id-type="pmid">28561327</pub-id><pub-id pub-id-type="pmcid">PMC6731037</pub-id></element-citation><mixed-citation id="mc-CR17" publication-type="journal">Ajmani, G. S., Suh, H. H., Wroblewski, K. E. &amp; Pinto, J. M. Smoking and olfactory dysfunction: A systematic literature review and meta-analysis. <italic toggle="yes">Laryngoscope</italic><bold>127</bold> (8), 1753&#8211;1761 (2017).<pub-id pub-id-type="pmid">28561327</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/lary.26558</pub-id><pub-id pub-id-type="pmcid">PMC6731037</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><mixed-citation publication-type="other">Agarwal, K., Schaffe-Odeleye, T., Marzouk, M. &amp; Joseph, P. V. Reduced bitter taste and enhanced appetitive odor identification in individuals at risk for alcohol use disorder: National Health and Nutrition Examination Survey (NHANES) 2013&#8211;2014. J Stud Alcohol Drugs.<pub-id pub-id-type="doi" assigning-authority="pmc">10.15288/jsad.24-00104</pub-id><pub-id pub-id-type="pmid">39589797</pub-id></mixed-citation></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lamb</surname><given-names>YN</given-names></name><name name-style="western"><surname>Nintedanib</surname></name></person-group><article-title>A review in Fibrotic interstitial lung diseases</article-title><source>Drugs Apr</source><year>2021</year><volume>81</volume><issue>5</issue><fpage>575</fpage><lpage>586</lpage><pub-id pub-id-type="doi">10.1007/s40265-021-01487-0</pub-id><pub-id pub-id-type="pmcid">PMC8163683</pub-id><pub-id pub-id-type="pmid">33765296</pub-id></element-citation><mixed-citation id="mc-CR19" publication-type="journal">Lamb, Y. N. &amp; Nintedanib A review in Fibrotic interstitial lung diseases. <italic toggle="yes">Drugs Apr</italic>. <bold>81</bold> (5), 575&#8211;586 (2021).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40265-021-01487-0</pub-id><pub-id pub-id-type="pmcid">PMC8163683</pub-id><pub-id pub-id-type="pmid">33765296</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dudani</surname><given-names>S</given-names></name><etal/></person-group><article-title>Evaluation of Clear Cell, Papillary, and Chromophobe Renal Cell Carcinoma Metastasis Sites and Association with Survival</article-title><source>JAMA Netw. open. Jan</source><year>2021</year><volume>4</volume><issue>1</issue><fpage>e2021869</fpage><pub-id pub-id-type="doi">10.1001/jamanetworkopen.2020.21869</pub-id><pub-id pub-id-type="pmcid">PMC7821027</pub-id><pub-id pub-id-type="pmid">33475752</pub-id></element-citation><mixed-citation id="mc-CR20" publication-type="journal">Dudani, S. et al. Evaluation of clear cell, papillary, and chromophobe renal cell carcinoma metastasis sites and association with survival. <italic toggle="yes">JAMA Netw. Open</italic>. <bold>4</bold> (1), e2021869 (2021).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamanetworkopen.2020.21869</pub-id><pub-id pub-id-type="pmcid">PMC7821027</pub-id><pub-id pub-id-type="pmid">33475752</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><mixed-citation publication-type="other">Zheng, Q. et al. Mortality and survival in idiopathic pulmonary fibrosis: A systematic review and meta-analysis. <italic toggle="yes">ERJ Open. Res.</italic><bold>8</bold>(1). (2022).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1183/23120541.00591-2021</pub-id><pub-id pub-id-type="pmcid">PMC8918939</pub-id><pub-id pub-id-type="pmid">35295232</pub-id></mixed-citation></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yilma</surname><given-names>M</given-names></name><etal/></person-group><article-title>Survival outcomes among patients with Hepatocellular Carcinoma in a large Integrated US Health System</article-title><source>JAMA Netw. Open.</source><year>2024</year><volume>7</volume><issue>9</issue><fpage>e2435066</fpage><pub-id pub-id-type="doi">10.1001/jamanetworkopen.2024.35066</pub-id><pub-id pub-id-type="pmid">39316399</pub-id><pub-id pub-id-type="pmcid">PMC11423175</pub-id></element-citation><mixed-citation id="mc-CR22" publication-type="journal">Yilma, M. et al. Survival outcomes among patients with Hepatocellular Carcinoma in a large Integrated US Health System. <italic toggle="yes">JAMA Netw. Open.</italic><bold>7</bold> (9), e2435066 (2024).<pub-id pub-id-type="pmid">39316399</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamanetworkopen.2024.35066</pub-id><pub-id pub-id-type="pmcid">PMC11423175</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rose</surname><given-names>TL</given-names></name><name name-style="western"><surname>Kim</surname><given-names>WY</given-names></name></person-group><article-title>Renal cell carcinoma: a review</article-title><source>JAMA</source><year>2024</year><volume>332</volume><issue>12</issue><fpage>1001</fpage><lpage>1010</lpage><pub-id pub-id-type="doi">10.1001/jama.2024.12848</pub-id><pub-id pub-id-type="pmid">39196544</pub-id><pub-id pub-id-type="pmcid">PMC11790279</pub-id></element-citation><mixed-citation id="mc-CR23" publication-type="journal">Rose, T. L. &amp; Kim, W. Y. Renal cell carcinoma: A review. <italic toggle="yes">JAMA</italic><bold>332</bold> (12), 1001&#8211;1010 (2024).<pub-id pub-id-type="pmid">39196544</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2024.12848</pub-id><pub-id pub-id-type="pmcid">PMC11790279</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boers-Doets</surname><given-names>CB</given-names></name><etal/></person-group><article-title>Oral adverse events associated with tyrosine kinase and mammalian target of rapamycin inhibitors in renal cell carcinoma: a structured literature review</article-title><source>Oncologist</source><year>2012</year><volume>17</volume><issue>1</issue><fpage>135</fpage><lpage>144</lpage><pub-id pub-id-type="doi">10.1634/theoncologist.2011-0111</pub-id><pub-id pub-id-type="pmid">22207567</pub-id><pub-id pub-id-type="pmcid">PMC3267813</pub-id></element-citation><mixed-citation id="mc-CR24" publication-type="journal">Boers-Doets, C. B. et al. Oral adverse events associated with tyrosine kinase and mammalian target of rapamycin inhibitors in renal cell carcinoma: A structured literature review. <italic toggle="yes">Oncologist</italic><bold>17</bold> (1), 135&#8211;144 (2012).<pub-id pub-id-type="pmid">22207567</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1634/theoncologist.2011-0111</pub-id><pub-id pub-id-type="pmcid">PMC3267813</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Epstein</surname><given-names>JB</given-names></name><name name-style="western"><surname>Barasch</surname><given-names>A</given-names></name></person-group><article-title>Taste disorders in cancer patients: pathogenesis, and approach to assessment and management</article-title><source>Oral Oncol.</source><year>2010</year><volume>46</volume><issue>2</issue><fpage>77</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1016/j.oraloncology.2009.11.008</pub-id><pub-id pub-id-type="pmid">20036797</pub-id></element-citation><mixed-citation id="mc-CR25" publication-type="journal">Epstein, J. B. &amp; Barasch, A. Taste disorders in cancer patients: Pathogenesis, and approach to assessment and management. <italic toggle="yes">Oral Oncol.</italic><bold>46</bold> (2), 77&#8211;81 (2010).<pub-id pub-id-type="pmid">20036797</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.oraloncology.2009.11.008</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zheng</surname><given-names>X</given-names></name><etal/></person-group><article-title>[Development and homeostasis of taste buds in mammals]. <italic toggle="yes">Hua Xi Kou Qiang Yi Xue Za Zhi&#8201;=&#8201;Huaxi Kouqiang Yixue Zazhi&#8201;=&#8201;West</italic></article-title><source>China J. Stomatology Oct.</source><year>2018</year><volume>1</volume><issue>5</issue><fpage>552</fpage><lpage>558</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.7518/hxkq.2018.05.016</pub-id><pub-id pub-id-type="pmcid">PMC7041142</pub-id><pub-id pub-id-type="pmid">30465351</pub-id></element-citation><mixed-citation id="mc-CR26" publication-type="journal">Zheng, X. et al. [Development and homeostasis of taste buds in mammals]. <italic toggle="yes">Hua Xi Kou Qiang Yi Xue Za Zhi&#8201;=&#8201;Huaxi Kouqiang Yixue Zazhi&#8201;=&#8201;West</italic>. <italic toggle="yes">China J. Stomatol.</italic><bold>1</bold> (5), 552&#8211;558 (2018).<pub-id pub-id-type="doi" assigning-authority="pmc">10.7518/hxkq.2018.05.016</pub-id><pub-id pub-id-type="pmcid">PMC7041142</pub-id><pub-id pub-id-type="pmid">30465351</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kanayama</surname><given-names>S</given-names></name><etal/></person-group><article-title>Analysis of soluble vascular endothelial growth factor receptor-1 secreted from cultured corneal and oral mucosal epithelial cell sheets in vitro</article-title><source>Br. J. Ophthalmol. Feb</source><year>2009</year><volume>93</volume><issue>2</issue><fpage>263</fpage><lpage>267</lpage><pub-id pub-id-type="doi">10.1136/bjo.2008.141580</pub-id><pub-id pub-id-type="pmid">19174402</pub-id></element-citation><mixed-citation id="mc-CR27" publication-type="journal">Kanayama, S. et al. Analysis of soluble vascular endothelial growth factor receptor-1 secreted from cultured corneal and oral mucosal epithelial cell sheets in vitro. <italic toggle="yes">Br. J. Ophthalmol.</italic>. <bold>93</bold> (2), 263&#8211;267 (2009).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bjo.2008.141580</pub-id><pub-id pub-id-type="pmid">19174402</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Katoh</surname><given-names>Y</given-names></name><name name-style="western"><surname>Katoh</surname><given-names>M</given-names></name></person-group><article-title>Comparative integromics on VEGF family members</article-title><source>Int. J. Oncol. Jun</source><year>2006</year><volume>28</volume><issue>6</issue><fpage>1585</fpage><lpage>1589</lpage><pub-id pub-id-type="pmid">16685460</pub-id></element-citation><mixed-citation id="mc-CR28" publication-type="journal">Katoh, Y. &amp; Katoh, M. Comparative integromics on VEGF family members. <italic toggle="yes">Int. J. Oncol.</italic><bold>28</bold> (6), 1585&#8211;1589 (2006).<pub-id pub-id-type="pmid">16685460</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Naik</surname><given-names>S</given-names></name><name name-style="western"><surname>Dothager</surname><given-names>RS</given-names></name><name name-style="western"><surname>Marasa</surname><given-names>J</given-names></name><name name-style="western"><surname>Lewis</surname><given-names>CL</given-names></name><name name-style="western"><surname>Piwnica-Worms</surname><given-names>D</given-names></name></person-group><article-title>Vascular endothelial growth factor Receptor-1 is synthetic Lethal to aberrant beta-catenin activation in Colon cancer</article-title><source>Clin. cancer Research: Official J. Am. Association Cancer Res. Dec.</source><year>2009</year><volume>15</volume><issue>24</issue><fpage>7529</fpage><lpage>7537</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-09-0336</pub-id><pub-id pub-id-type="pmcid">PMC2797340</pub-id><pub-id pub-id-type="pmid">20008853</pub-id></element-citation><mixed-citation id="mc-CR29" publication-type="journal">Naik, S., Dothager, R. S., Marasa, J., Lewis, C. L. &amp; Piwnica-Worms, D. Vascular endothelial growth factor Receptor-1 is synthetic Lethal to aberrant beta-catenin activation in Colon cancer. <italic toggle="yes">Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res.</italic><bold>15</bold> (24), 7529&#8211;7537 (2009).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1078-0432.CCR-09-0336</pub-id><pub-id pub-id-type="pmcid">PMC2797340</pub-id><pub-id pub-id-type="pmid">20008853</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carmeliet</surname><given-names>P</given-names></name><name name-style="western"><surname>Ruiz de Almodovar</surname><given-names>C</given-names></name></person-group><article-title>VEGF ligands and receptors: implications in neurodevelopment and neurodegeneration</article-title><source>Cell. Mol. life Sciences: CMLS May</source><year>2013</year><volume>70</volume><issue>10</issue><fpage>1763</fpage><lpage>1778</lpage><pub-id pub-id-type="doi">10.1007/s00018-013-1283-7</pub-id><pub-id pub-id-type="pmcid">PMC11113464</pub-id><pub-id pub-id-type="pmid">23475071</pub-id></element-citation><mixed-citation id="mc-CR30" publication-type="journal">Carmeliet, P. &amp; Ruiz de Almodovar, C. VEGF ligands and receptors: Implications in neurodevelopment and neurodegeneration. <italic toggle="yes">Cell. Mol. Life Sci. CMLS</italic>. <bold>70</bold> (10), 1763&#8211;1778 (2013).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00018-013-1283-7</pub-id><pub-id pub-id-type="pmcid">PMC11113464</pub-id><pub-id pub-id-type="pmid">23475071</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>H</given-names></name><name name-style="western"><surname>Deng</surname><given-names>L</given-names></name><name name-style="western"><surname>Qin</surname><given-names>X</given-names></name></person-group><article-title>[Development of an olfactory epithelial organoid culture system based on small molecule screening]</article-title><source>Sheng Wu gong. Cheng Xue bao = Chin. J. Biotechnol. Jan</source><year>2023</year><volume>25</volume><issue>1</issue><fpage>318</fpage><lpage>336</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.13345/j.cjb.220244</pub-id><pub-id pub-id-type="pmid">36738219</pub-id></element-citation><mixed-citation id="mc-CR31" publication-type="journal">Wang, H., Deng, L. &amp; Qin, X. [Development of an olfactory epithelial organoid culture system based on small molecule screening]. <italic toggle="yes">Sheng Wu gong. Cheng Xue bao = Chin. J. Biotechnol.</italic>. <bold>25</bold> (1), 318&#8211;336 (2023).<pub-id pub-id-type="doi" assigning-authority="pmc">10.13345/j.cjb.220244</pub-id><pub-id pub-id-type="pmid">36738219</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>AP</given-names></name><name name-style="western"><surname>Davidson</surname><given-names>T</given-names></name></person-group><article-title>Posttraumatic anosmia secondary to central nervous system injury</article-title><source>Am. J. Rhinology Nov-Dec</source><year>2008</year><volume>22</volume><issue>6</issue><fpage>606</fpage><lpage>607</lpage><pub-id pub-id-type="doi">10.2500/ajr.2008.22.3238</pub-id><pub-id pub-id-type="pmid">19178798</pub-id></element-citation><mixed-citation id="mc-CR32" publication-type="journal">Wu, A. P. &amp; Davidson, T. Posttraumatic anosmia secondary to central nervous system injury. <italic toggle="yes">Am. J. Rhinol.</italic><bold>22</bold> (6), 606&#8211;607 (2008).<pub-id pub-id-type="doi" assigning-authority="pmc">10.2500/ajr.2008.22.3238</pub-id><pub-id pub-id-type="pmid">19178798</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schiffman</surname><given-names>SS</given-names></name></person-group><article-title>Taste and smell losses in normal aging and disease</article-title><source>Jama Oct.</source><year>1997</year><volume>22&#8211;29</volume><issue>16</issue><fpage>1357</fpage><lpage>1362</lpage><pub-id pub-id-type="doi">10.1001/jama.1997.03550160077042</pub-id><pub-id pub-id-type="pmid">9343468</pub-id></element-citation><mixed-citation id="mc-CR33" publication-type="journal">Schiffman, S. S. Taste and smell losses in normal aging and disease. <italic toggle="yes">Jama</italic><bold>22&#8211;29</bold> (16), 1357&#8211;1362 (1997).<pub-id pub-id-type="pmid">9343468</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jin</surname><given-names>K</given-names></name><etal/></person-group><article-title>Vascular endothelial growth factor (VEGF) stimulates neurogenesis in vitro and in vivo</article-title><source>Proc. Natl. Acad. Sci. United States Am. Sep.</source><year>2002</year><volume>3</volume><issue>18</issue><fpage>11946</fpage><lpage>11950</lpage><pub-id pub-id-type="doi">10.1073/pnas.182296499</pub-id><pub-id pub-id-type="pmcid">PMC129374</pub-id><pub-id pub-id-type="pmid">12181492</pub-id></element-citation><mixed-citation id="mc-CR34" publication-type="journal">Jin, K. et al. Vascular endothelial growth factor (VEGF) stimulates neurogenesis in vitro and in vivo. <italic toggle="yes">Proc. Natl. Acad. Sci. U. S. A.</italic><bold>3</bold> (18), 11946&#8211;11950 (2002).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.182296499</pub-id><pub-id pub-id-type="pmcid">PMC129374</pub-id><pub-id pub-id-type="pmid">12181492</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wittko</surname><given-names>IM</given-names></name><etal/></person-group><article-title>VEGFR-1 regulates adult olfactory bulb neurogenesis and migration of neural progenitors in the rostral migratory stream in vivo</article-title><source>J. Neuroscience: Official J. Soc. Neurosci. Jul</source><year>2009</year><volume>8</volume><issue>27</issue><fpage>8704</fpage><lpage>8714</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.5527-08.2009</pub-id><pub-id pub-id-type="pmcid">PMC3865485</pub-id><pub-id pub-id-type="pmid">19587277</pub-id></element-citation><mixed-citation id="mc-CR35" publication-type="journal">Wittko, I. M. et al. VEGFR-1 regulates adult olfactory bulb neurogenesis and migration of neural progenitors in the rostral migratory stream in vivo. <italic toggle="yes">J. Neurosci. Off. J. Soc. Neurosci.</italic>. <bold>8</bold> (27), 8704&#8211;8714 (2009).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1523/JNEUROSCI.5527-08.2009</pub-id><pub-id pub-id-type="pmcid">PMC3865485</pub-id><pub-id pub-id-type="pmid">19587277</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mohapel</surname><given-names>P</given-names></name><name name-style="western"><surname>Frielingsdorf</surname><given-names>H</given-names></name><name name-style="western"><surname>Haggblad</surname><given-names>J</given-names></name><name name-style="western"><surname>Zachrisson</surname><given-names>O</given-names></name><name name-style="western"><surname>Brundin</surname><given-names>P</given-names></name></person-group><article-title>Platelet-derived growth factor (PDGF-BB) and brain-derived neurotrophic factor (BDNF) induce striatal neurogenesis in adult rats with 6-hydroxydopamine lesions</article-title><source>Neuroscience</source><year>2005</year><volume>132</volume><issue>3</issue><fpage>767</fpage><lpage>776</lpage><pub-id pub-id-type="doi">10.1016/j.neuroscience.2004.11.056</pub-id><pub-id pub-id-type="pmid">15837137</pub-id></element-citation><mixed-citation id="mc-CR36" publication-type="journal">Mohapel, P., Frielingsdorf, H., Haggblad, J., Zachrisson, O. &amp; Brundin, P. Platelet-derived growth factor (PDGF-BB) and brain-derived neurotrophic factor (BDNF) induce striatal neurogenesis in adult rats with 6-hydroxydopamine lesions. <italic toggle="yes">Neuroscience</italic><bold>132</bold> (3), 767&#8211;776 (2005).<pub-id pub-id-type="pmid">15837137</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuroscience.2004.11.056</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Beecher</surname><given-names>K</given-names></name><name name-style="western"><surname>Hafner</surname><given-names>LM</given-names></name><name name-style="western"><surname>Ekberg</surname><given-names>J</given-names></name><name name-style="western"><surname>St John</surname><given-names>JA</given-names></name><name name-style="western"><surname>Chehrehasa</surname><given-names>F</given-names></name></person-group><article-title>Combined VEGF/PDGF improves olfactory regeneration after unilateral bulbectomy in mice</article-title><source>Neural Regeneration Res. Oct.</source><year>2018</year><volume>13</volume><issue>10</issue><fpage>1820</fpage><lpage>1826</lpage><pub-id pub-id-type="doi">10.4103/1673-5374.238713</pub-id><pub-id pub-id-type="pmcid">PMC6128065</pub-id><pub-id pub-id-type="pmid">30136698</pub-id></element-citation><mixed-citation id="mc-CR37" publication-type="journal">Beecher, K., Hafner, L. M., Ekberg, J., St John, J. A. &amp; Chehrehasa, F. Combined VEGF/PDGF improves olfactory regeneration after unilateral bulbectomy in mice. <italic toggle="yes">Neural Regen. Res.</italic><bold>13</bold> (10), 1820&#8211;1826 (2018).<pub-id pub-id-type="doi" assigning-authority="pmc">10.4103/1673-5374.238713</pub-id><pub-id pub-id-type="pmcid">PMC6128065</pub-id><pub-id pub-id-type="pmid">30136698</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Beites</surname><given-names>CL</given-names></name><name name-style="western"><surname>Kawauchi</surname><given-names>S</given-names></name><name name-style="western"><surname>Crocker</surname><given-names>CE</given-names></name><name name-style="western"><surname>Calof</surname><given-names>AL</given-names></name></person-group><article-title>Identification and molecular regulation of neural stem cells in the olfactory epithelium</article-title><source>Exp. Cell. Res.</source><year>2005</year><volume>306</volume><issue>2</issue><fpage>309</fpage><lpage>316</lpage><pub-id pub-id-type="doi">10.1016/j.yexcr.2005.03.027</pub-id><pub-id pub-id-type="pmid">15925585</pub-id></element-citation><mixed-citation id="mc-CR38" publication-type="journal">Beites, C. L., Kawauchi, S., Crocker, C. E. &amp; Calof, A. L. Identification and molecular regulation of neural stem cells in the olfactory epithelium. <italic toggle="yes">Exp. Cell. Res.</italic><bold>306</bold> (2), 309&#8211;316 (2005).<pub-id pub-id-type="pmid">15925585</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.yexcr.2005.03.027</pub-id></mixed-citation></citation-alternatives></ref></ref-list></back></article></pmc-articleset>